[Skip to Content]
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
June 2012

The Use of Anti–Interleukin-12/23 Agents and Major Adverse Cardiovascular Events

Author Affiliations
 

SECTION EDITOR: MICHAEL BIGBY, MD; ASSISTANT SECTION EDITORS: OLIVIER CHOSIDOW, MD, PhD; ROBERT P. DELLAVALLE, MD, PhD, MSPH; DAIHUNG DO, MD; URBÀ GONZÁLEZ, MD, PhD; CATALIN M. POPESCU, MD, PhD; HYWEL WILLIAMS, MSc, PhD, FRCP

Arch Dermatol. 2012;148(6):753-754. doi:10.1001/archdermatol.2011.2618

Commentary on: Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trialsRyan C, Leonardi CL, Krueger JG, et al. JAMA. 2011;306(8):864-871

Question: Is the use of anti–interleukin (IL)-12 and IL-23 agents to treat chronic plaque psoriasis associated with an increase in major adverse cardiovascular events?

Objective: To evaluate a possible association between biologic therapies for CPP [chronic plaque psoriasis] and MACEs [major adverse cardiovascular events] via meta-analysis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×